

香港聯合交易所有限公司
(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

通告 CIRCULAR

Subject: **SZSE-Listed YANAN BICON PHARMACEUTICAL (*ST) (SZSE Security Code: 002411)**

Enquiry: **Participant General Enquiry Hotline¹ (Tel : 2840 3626 E-mail : trd@hkex.com.hk)**

Exchange Participants (“EPs”) are requested to note that YANAN BICON PHARMACEUTICAL (*ST) (SZSE Security Code: 002411) (“YANAN BICON PHARMA”) has issued an [announcement](#) (Chinese only) on Shenzhen Stock Exchange (“SZSE”) website. It states that the security will enter into a Delisting Arrangement Period (退市整理期) for 15 trading days (the “Delisting Arrangement Period”), i.e. the final period during which YANAN BICON PHARMA shares can be traded on SZSE before they are delisted from SZSE.

The Delisting Arrangement Period will commence from 19 June 2023 and trading of YANAN BICON PHARMA shares on SZSE will be resumed on the same date. The Delisting Arrangement Period is currently expected to end on 11 July 2023. Afterwards, YANAN BICON PHARMA shares will be delisted from SZSE. YANAN BICON PHARMA shares are Special China Connect Securities which are eligible for sell only in Northbound trading during the Delisting Arrangement Period.

For any EP who wishes to sell any YANAN BICON PHARMA shares through the use of the China Connect Service, it may only be able to do so on or before the end of the Delisting Arrangement Period. Upon completion of the delisting from SZSE, YANAN BICON PHARMA shares will be removed from the list of Special China Connect Securities and EPs will no longer be allowed to input any buy or sell order in respect of YANAN BICON PHARMA shares through the use of the China Connect Service.

EPs should also note that Hong Kong Securities Clearing Company Limited (“HKSCC”) will cease to render services in respect of the YANAN BICON PHARMA shares upon their delisting from SZSE. Please refer to the relevant circular(s) issued by HKSCC for details.

¹All calls to and from the Participant General Enquiry Hotline may be recorded. HKEX Privacy Policy Statement is available [here](#).

EPs are urged to consider the potential liquidity risk and other limitations as well as restrictions on holding YANAN BICON PHARMA shares after the end of the Delisting Arrangement Period and promptly take all necessary actions where appropriate. EPs are reminded to refer to announcement(s) available on SZSE website for details on the delisting of YANAN BICON PHARMA from SZSE and any other subsequent updates.

Ken Wong
Senior Vice President
Trading Department
Operations Division